The PRAGUE-25 Study

05/08/2026

Talking Points

0:00

7:57

Pavel Osmancik and C. Michael Gibson discuss whether catheter ablation is superior to risk factor modification with antiarrythmic drugs for the treatment of AF.

D'autres épisodes de "Talking Points"

The Evolut Low Risk Trial
04/11/2026
5:11
Michael J. Reardon and C. Michael Gibson discuss the 5-year outcomes of TAVR or SAVR in low-risk patients with AS.
The BHF PROTECT-TAVI Trial
14/10/2026
5:42
Can routine cerebral embolic protection reduce stroke risk in TAVI? Rajesh Kharbanda and C. Michael Gibson discuss.
Ne ratez aucun épisode de “Talking Points” et abonnez-vous gratuitement à ce podcast dans l'application GetPodcast.
The FAME 3 Trial
16/09/2026
9:02
William Fearon and C. Michael Gibson break down the final 5-year follow-up of the study comparing FFR-guided PCI vs CABG for patients with three-vessel CAD.
The TRILUMINATE Pivotal Trial
02/09/2026
8:04
Saibal Kar and C. Michael Gibson look at the 2-year outcomes of transcatheter edge-to-edge repair for tricuspid regurgitation.
The PRAGUE-25 Study
05/08/2026
7:57
Pavel Osmancik and C. Michael Gibson discuss whether catheter ablation is superior to risk factor modification with antiarrythmic drugs for the treatment of AF.
The BETAMI-DANBLOCK Trial
22/07/2026
8:38
How does discontinuing beta-blockers after MI affect outcomes in patients without HF? Dan Atar and C. Michael Gibson break it down.
New York Valves 2026: Implications of the Proposed National Coverage Determination for TAVI
01/07/2026
1:33:28
In one of the most thought-provoking sessions at New York Valves 2026, Michael Mack and Roxana Mehran moderate a panel discussion looking at the future of TAVI from all angles.
The PROCTOR Trial
03/06/2026
8:35
Ruben de Winter and C. Michael Gibson compare clinical outcomes of native vessel versus SVG PCI for patients with prior CABG.
The SELUTION DeNovo Trial
20/05/2026
5:08
Christian M. Spaulding and C. Michael Gibson look at the 1-year results from the study comparing sirolimus-eluting DCB with DES for de novo coronary lesions.
The VESALIUS-CV Trial
06/05/2026
7:21
Paul Burton and C. Michael Gibson discuss the effects of adding evolocumab for patients at high risk for CV events but without prior MI or stroke.

Plus d'épisodes

Découvrez le meilleur des podcasts sur l'application GetPodcast.

Abonnez-vous à tous vos podcasts préférés, écoutez les épisodes sans connexion internet et recevez des recommandations de podcasts passionnants.

Une entreprise de

The PRAGUE-25 Study

Talking Points

D'autres épisodes de "Talking Points"

The Evolut Low Risk Trial

The BHF PROTECT-TAVI Trial

The FAME 3 Trial

The TRILUMINATE Pivotal Trial

The PRAGUE-25 Study

The BETAMI-DANBLOCK Trial

New York Valves 2026: Implications of the Proposed National Coverage Determination for TAVI

The PROCTOR Trial

The SELUTION DeNovo Trial

The VESALIUS-CV Trial